EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab

Código QR

EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab

Chad A Reade1, Apar Kishor Ganti1,21Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA; 2Section of Oncology-Hematology, Department of internal Medicine, VA Medical Center, Omaha, NE, USAAbstract: Chemotherapy alone has limited ability to significantly improve sur...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chad A Reade, Apar Kishor Ganti
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/8d4fb8e88384411c8632dee95a7350c3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Cetuximab and biomarkers in non-small-cell lung carcinoma
por: Patil N, et al.
Publicado: (2012)

AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy
por: Jordi Bertran-Alamillo, et al.
Publicado: (2019)

Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer
por: Nathaniel Wiest, et al.
Publicado: (2021)

Cetuximab-Coated Thermo-Sensitive Liposomes Loaded with Magnetic Nanoparticles and Doxorubicin for Targeted EGFR-Expressing Breast Cancer Combined Therapy
por: Dorjsuren B, et al.
Publicado: (2020)

Targeting MERTK and AXL in <i>EGFR</i> Mutant Non-Small Cell Lung Cancer
por: Dan Yan, et al.
Publicado: (2021)

Non-small cell lung cancer: the era of targeted therapy
por: Antonoff MB, et al.
Publicado: (2012)

Adjuvant targeted therapy for non-small cell lung cancer
por: Konstantin K. Laktionov, et al.
Publicado: (2020)

Targeted treatment of mutated EGFR-expressing non-small-cell lung cancer: focus on erlotinib with companion diagnostics
por: Karachaliou N, et al.
Publicado: (2014)

EGFR Targeted Cetuximab-Valine-Citrulline (vc)-Doxorubicin Immunoconjugates- Loaded Bovine Serum Albumin (BSA) Nanoparticles for Colorectal Tumor Therapy
por: Ye Z, et al.
Publicado: (2021)

Clinical and surgical implications of EGFR mutations in non-small cell lung cancer
por: M. Yoon, et al.
Publicado: (2016)

Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
por: Ken Uchibori, et al.
Publicado: (2017)

Cell Behavior of Non-Small Cell Lung Cancer Is at EGFR and MicroRNAs Hands
por: Sarah Sayed Hassanein, et al.
Publicado: (2021)

Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR
por: Karan Seegobin, et al.
Publicado: (2021)

Anti-EGFR antibody 528 binds to domain III of EGFR at a site shifted from the cetuximab epitope
por: Koki Makabe, et al.
Publicado: (2021)

Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers
por: Tereza Vaclova, et al.
Publicado: (2021)

Effect of Epigallocatechin-3-Gallate on EGFR Signaling and Migration in Non-Small Cell Lung Cancer
por: Cristina Minnelli, et al.
Publicado: (2021)

EGFR exon-level biomarkers of the response to bevacizumab/erlotinib in non-small cell lung cancer.
por: Florent Baty, et al.
Publicado: (2013)

First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
por: Nguyen KS, et al.
Publicado: (2012)

Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer
por: D&#39;Arcangelo M, et al.
Publicado: (2013)

Cetuximab-conjugated iron oxide nanoparticles for cancer imaging and therapy
por: Tseng SH, et al.
Publicado: (2015)

Evaluation of the Idylla ctEGFR mutation assay to detect EGFR mutations in plasma from patients with non-small cell lung cancers
por: Pauline Gilson, et al.
Publicado: (2021)

Targeted therapy for LIMD1-deficient non-small cell lung cancer subtypes
por: Kathryn Davidson, et al.
Publicado: (2021)

The Prognostic Role of Blood Inflammatory Biomarkers and EGFR Mutation Status in Stage IIIA/N2 Non-Small Cell Lung Cancer Patients Treated With Trimodality Therapy
por: Hui Yang, et al.
Publicado: (2021)

Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions
por: Chie Morita, et al.
Publicado: (2021)

Contribution of p53 in sensitivity to EGFR tyrosine kinase inhibitors in non-small cell lung cancer
por: Sangyong Jung, et al.
Publicado: (2021)

The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer
por: Barbara Melosky, et al.
Publicado: (2021)

New targeted treatments for non-small-cell lung cancer – role of nivolumab
por: Zago G, et al.
Publicado: (2016)

In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts
por: Sreeranganathan M, et al.
Publicado: (2017)

Comparison of the outcome between immunotherapy alone or in combination with chemotherapy in EGFR-mutant non-small cell lung cancer
por: Chia-I Shen, et al.
Publicado: (2021)

Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung Cancer
por: Brazel D, et al.
Publicado: (2021)

Genomic signatures define three subtypes of EGFR-mutant stage II–III non-small-cell lung cancer with distinct adjuvant therapy outcomes
por: Si-Yang Liu, et al.
Publicado: (2021)

In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts [Corrigendum]
por: Sreeranganathan M, et al.
Publicado: (2019)

Functionalized selenium nanoparticles for targeted delivery of doxorubicin to improve non-small-cell lung cancer therapy
por: Xia Y, et al.
Publicado: (2018)

Editorial: New Advances in Non-small Cell Lung Cancer Management: Immune Modulation and Targeted Therapies
por: Thierry Berghmans, et al.
Publicado: (2021)

Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study
por: Taichi Miyawaki, et al.
Publicado: (2021)

PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup.
por: Lei Wang, et al.
Publicado: (2014)

Safety of Surgery after Neoadjuvant Targeted Therapies in Non-Small Cell Lung Cancer: A Narrative Review
por: Tomasz Marjanski, et al.
Publicado: (2021)

Preliminary comparison of neuropsychological performance in patients with non-small-cell lung cancer treated with chemotherapy or targeted therapy
por: Kang HL, et al.
Publicado: (2019)

Prospects for the development of adjuvant therapy for non-small cell lung cancer
por: K. K. Laktionov, et al.
Publicado: (2020)

Comparison of the efficacy of first-line therapy with different generations of EGFR tyrosine kinase inhibitors in patients with advanced EGFR-associated non-small cell lung cancer: a network meta-analysis of overall survival data
por: Alexey A. Bogdanov, et al.
Publicado: (2021)